FDA Grants Priority Review for Eagle Pharmaceuticals' Ryanodex NDA for the Treatment of Exertional Heat Stroke

Source :: Pharma Business Week. April 10, 2017, 79
Publication Year :: 2017
Abstract: 2017 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Eagle Pharmaceuticals (Nasdaq:EGRX) ('Eagle' or 'the Company') announced that their 505(b)(2) New Drug Application [...]

Subjects :: United States. Food and Drug Administration
Heatstroke -- Drug therapy
Eagles
Dantrolene -- Evaluation
Prescriptions (Drugs) -- Evaluation
Business
Pharmaceuticals and cosmetics industries
Health
Ryanodex (Medication) -- Evaluation

Tools